Which has higher valuation & earnings, NVS or GSK?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.42 $13.98B $6.63 23.35 GSK $43.07B 2.41 $7.54B $3.85 13.35

Is NVS or GSK more profitable?

Novartis has a net margin of 23.29% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% GSK 17.82% 44.28% 11.49%

Does the media favor NVS or GSK?

In the previous week, Novartis had 12 more articles in the media than GSK. MarketBeat recorded 31 mentions for Novartis and 19 mentions for GSK. Novartis' average media sentiment score of 0.86 beat GSK's score of 0.59 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 19 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive GSK 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, AZN or GSK?

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.45 $10.23B $6.66 25.33 GSK $43.07B 2.41 $7.54B $3.85 13.35

Is AZN or GSK more profitable?

GSK has a net margin of 17.82% compared to Astrazeneca's net margin of 17.19%. GSK's return on equity of 44.28% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.19% 30.86% 12.68% GSK 17.82% 44.28% 11.49%

Does the media prefer AZN or GSK?

In the previous week, Astrazeneca had 22 more articles in the media than GSK. MarketBeat recorded 41 mentions for Astrazeneca and 19 mentions for GSK. Astrazeneca's average media sentiment score of 0.98 beat GSK's score of 0.59 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 27 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive GSK 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, GSK or NVO?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.41 $7.54B $3.85 13.35 Novo Nordisk A/S $46.80B 4.65 $15.51B $4.26 11.45

Is GSK or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media refer more to GSK or NVO?

In the previous week, Novo Nordisk A/S had 22 more articles in the media than GSK. MarketBeat recorded 41 mentions for Novo Nordisk A/S and 19 mentions for GSK. GSK's average media sentiment score of 0.59 beat Novo Nordisk A/S's score of 0.13 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 15 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 12 Negative mention(s) 6 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SNY or GSK?

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.13 $8.84B $3.58 12.11 GSK $43.07B 2.41 $7.54B $3.85 13.35

Is SNY or GSK more profitable?

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% GSK 17.82% 44.28% 11.49%

Does the media favor SNY or GSK?

In the previous week, GSK had 12 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for GSK and 7 mentions for Sanofi. Sanofi's average media sentiment score of 0.68 beat GSK's score of 0.59 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GSK 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GSK or TAK?

GSK currently has a consensus target price of $53.00, indicating a potential upside of 3.15%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.20 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better valuation & earnings, GSK or TAK?

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.41 $7.54B $3.85 13.35 Takeda Pharmaceutical $28.32B 1.95 -$1.01B $0.39 44.19

Does the media prefer GSK or TAK?

In the previous week, GSK had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for GSK and 5 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 0.59 beat Takeda Pharmaceutical's score of 0.46 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GSK (GSK) Competitors

$51.38 +0.03 (+0.06%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$51.41 +0.03 (+0.06%)

As of 07/24/2026 07:34 PM Eastern

Compare

GSK vs. NVS, AZN, NVO, SNY, and TAK

Should you buy GSK stock or one of its competitors? MarketBeat compares GSK with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GSK include Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does GSK compare to Novartis?

Novartis (NYSE:NVS) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Novartis has a net margin of 23.29% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
GSK	17.82%	44.28%	11.49%

Novartis presently has a consensus target price of $141.20, suggesting a potential downside of 8.81%. GSK has a consensus target price of $53.00, suggesting a potential upside of 3.15%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
GSK	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20

13.1% of Novartis shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Novartis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.42	$13.98B	$6.63	23.35
GSK	$43.07B	2.41	$7.54B	$3.85	13.35

In the previous week, Novartis had 12 more articles in the media than GSK. MarketBeat recorded 31 mentions for Novartis and 19 mentions for GSK. Novartis' average media sentiment score of 0.86 beat GSK's score of 0.59 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	19 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Novartis pays out 46.5% of its earnings in the form of a dividend. GSK pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats GSK on 13 of the 19 factors compared between the two stocks.

How does GSK compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and GSK (NYSE:GSK) are both large-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Astrazeneca presently has a consensus target price of $211.00, suggesting a potential upside of 25.09%. GSK has a consensus target price of $53.00, suggesting a potential upside of 3.15%. Given Astrazeneca's stronger consensus rating and higher possible upside, equities research analysts plainly believe Astrazeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
GSK	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20

In the previous week, Astrazeneca had 22 more articles in the media than GSK. MarketBeat recorded 41 mentions for Astrazeneca and 19 mentions for GSK. Astrazeneca's average media sentiment score of 0.98 beat GSK's score of 0.59 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	27 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.45	$10.23B	$6.66	25.33
GSK	$43.07B	2.41	$7.54B	$3.85	13.35

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. GSK pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a net margin of 17.82% compared to Astrazeneca's net margin of 17.19%. GSK's return on equity of 44.28% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
GSK	17.82%	44.28%	11.49%

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Astrazeneca beats GSK on 12 of the 19 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

GSK currently has a consensus target price of $53.00, suggesting a potential upside of 3.15%. Novo Nordisk A/S has a consensus target price of $65.56, suggesting a potential upside of 34.46%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.41	$7.54B	$3.85	13.35
Novo Nordisk A/S	$46.80B	4.65	$15.51B	$4.26	11.45

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.6%. GSK pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 22 more articles in the media than GSK. MarketBeat recorded 41 mentions for Novo Nordisk A/S and 19 mentions for GSK. GSK's average media sentiment score of 0.59 beat Novo Nordisk A/S's score of 0.13 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	15 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	12 Negative mention(s)	6 Very Negative mention(s)	Neutral

15.7% of GSK shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats GSK on 13 of the 19 factors compared between the two stocks.

How does GSK compare to Sanofi?

Sanofi (NASDAQ:SNY) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
GSK	17.82%	44.28%	11.49%

Sanofi presently has a consensus target price of $49.50, suggesting a potential upside of 14.19%. GSK has a consensus target price of $53.00, suggesting a potential upside of 3.15%. Given Sanofi's stronger consensus rating and higher probable upside, equities research analysts clearly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
GSK	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20

14.0% of Sanofi shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sanofi has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, GSK had 12 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for GSK and 7 mentions for Sanofi. Sanofi's average media sentiment score of 0.68 beat GSK's score of 0.59 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.13	$8.84B	$3.58	12.11
GSK	$43.07B	2.41	$7.54B	$3.85	13.35

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Sanofi pays out 49.2% of its earnings in the form of a dividend. GSK pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

GSK beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does GSK compare to Takeda Pharmaceutical?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

GSK currently has a consensus target price of $53.00, indicating a potential upside of 3.15%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.41	$7.54B	$3.85	13.35
Takeda Pharmaceutical	$28.32B	1.95	-$1.01B	$0.39	44.19

15.7% of GSK shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. GSK pays out 46.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 123.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a net margin of 17.82% compared to Takeda Pharmaceutical's net margin of 4.31%. GSK's return on equity of 44.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

In the previous week, GSK had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for GSK and 5 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 0.59 beat Takeda Pharmaceutical's score of 0.46 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GSK beats Takeda Pharmaceutical on 16 of the 18 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$103.92B	$3.66B	$6.90B	$23.53B
Dividend Yield	3.49%	2.18%	2.67%	4.20%
P/E Ratio	13.35	21.48	27.14	30.96
Price / Sales	2.41	298.37	523.34	19.25
Price / Cash	8.55	59.51	26.39	18.55
Price / Book	4.98	7.89	10.30	4.73
Net Income	$7.54B	$23.81M	$3.60B	$1.07B
7 Day Performance	2.67%	-2.39%	-0.27%	-0.04%
1 Month Performance	-2.12%	-4.47%	-1.74%	-0.42%
1 Year Performance	35.38%	33.01%	18.24%	14.22%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	2.9705 of 5 stars	$51.38 +0.1%	$53.00 +3.2%	+35.4%	$103.92B	$43.07B	13.35	66,841	Trending News Upcoming Earnings Dividend Cut Analyst Forecast
NVS Novartis	2.8458 of 5 stars	$154.46 +3.3%	$141.20 -8.6%	+31.6%	$294.87B	$54.53B	22.14	75,267	Earnings Report
AZN Astrazeneca	4.564 of 5 stars	$167.02 +1.5%	$211.00 +26.3%	N/A	$259.08B	$58.74B	25.08	96,100	Short Interest Increase
NVO Novo Nordisk A/S	4.2055 of 5 stars	$49.38 -0.5%	$65.56 +32.8%	-32.0%	$220.49B	$46.80B	11.59	69,505
SNY Sanofi	3.4752 of 5 stars	$43.75 -0.5%	$49.50 +13.1%	-13.9%	$106.16B	$49.35B	12.23	74,846	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors